Company
Nuclera
The only end-to-end multiplex protein screening system that empowers you to perform your own protein design, screening, characterization, and small-scale expression in-house within days.
Also known as Nuclera Ltd
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Cambridge, Cambridgeshire, United Kingdom
- Founded
- 2013
- Employees
- 100-strongSource (opens in a new tab)
- Customers
- The protein scientists spearheading the next generation of breakthroughs
- Legal name
- Nuclera Ltd
- nuclera.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 17 September 2026
About
Nuclera exists to remove uncertainty from protein science. As the pioneer of multiplex protein screening, we help researchers start with clarity, so ideas move faster to result. We believe access to your protein should be a certainty, not a gamble. eProtein Discovery™ is how we deliver on that promise, but our aim is bigger: to make protein access routine for every lab, accelerate breakthroughs in human health, and empower scientists to spend more time on discovery and less on delay.
Funding snapshot
- Total raised
- $245MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series C, $87M2026-01-13
Funding rounds
- Series C
- $87M2026-01-13, Company stated
- Series C
- $75M2024, Company stated
- Series B
- $58M2022, Company stated
- Round, 2020
- $12M2020, Company stated
- Series A
- $12M2018, Company stated
- Seed
- $600K2014, Company stated
Products
- Hardware
- eProtein Discovery
Loading relationship preview